Moderna reports encouraging results on its mpox vaccine, as outbreaks in Africa spread
The emergence of a second mpox outbreak in which the virus is spreading from person…
Category: biotechnolgy
STAT+: Eli Lilly’s billions: Can the world’s most valuable pharma company keep inventing drugs at this pace?
On Tuesday, Eli Lilly unveiled a towering 346,000-square-foot laboratory in Boston’s Seaport District, a building…
Opinion: For national security, the U.S. must maintain its biotech dominance
For more than a century, the United States has been the undisputed leader in medical…
STAT+: Massachusetts lawmakers consider $1 billion proposal to bolster region’s life science leadership
Next stop: Beacon Hill. Governor Maura Healey’s long-awaited plan to double down on state funding…
STAT+: Doudna institute hatches plan to ‘cure hundreds of diseases’ left behind by CRISPR revolution
Researchers attending gene therapy meetings over the past couple years were liable to bump into…
STAT+: David Liu startup to focus on getting CRISPR therapy to hard-to-reach cells
David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching…
STAT+: Gene therapy is in crisis. For nine hours, the field’s leading minds looked for a solution
WASHINGTON — Jennifer Puck has successfully treated 10 children with a gene therapy for a…
STAT+: Sen. Cassidy wants to put a stop to FDA delays in drug review process
WASHINGTON – Sen. Bill Cassidy (R-La.) is looking into ways to speed up the Food…
STAT+: No more ‘playing God’: How the longevity field is trying to recast its work as serious science
SAN FRANCISCO — “Why is it in popular culture, if you want to live forever, you…
STAT+: As Ginkgo stock sinks, CEO Jason Kelly tries to win over drugmakers in San Francisco
SAN FRANCISCO — Ginkgo Bioworks CEO Jason Kelly is here trying to convince the world’s…
STAT+: Former Merck CEO: Democracy and the drug industry are both in danger
Ken Frazier, the former chief executive of Merck, has been the preeminent pharmaceutical CEO of…
STAT+: This billionaire has quietly driven Boston’s biotech industry for decades
Among the small bunch of billionaires that the local biotech industry has created, Tim Springer…
STAT+: European researchers seek greater stake in drug development in bid to improve access
As the price of new medicines weighs on health payers in Europe, universities are seeking…
STAT+: Bristol Myers Squibb to buy Turning Point Therapeutics for $4.1 billion to gain drugs targeting rare cancer mutations
Bristol Myers Squibb said Friday that it is acquiring Turning Point Therapeutics, a biotech that…
STAT+: The four senators who could make or break Democrats’ drug pricing ambitions
WASHINGTON — The fate of the Democratic party’s ambitious goal of allowing Medicare to negotiate…